PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32500755-10	2021	Moreover, naringin inhibited Ti particle-induced phosphorylation of p38 and p65.	naringin	10-18	mitogen-activated protein kinase 14	Homo sapiens	68-71	
35119637-8	2022	The effective parameters underlying the anticancer effects of naringenin and naringin include GSK3beta inactivation, suppression of the gene and protein activation of NF-kB and COX-2, JAK2/STAT3 downregulation, downregulation of intracellular adhesion molecules-1, upregulation of Notch1 and tyrocite-specific genes, and activation of p38/MAPK and caspase-3.	naringin	77-85	mitogen-activated protein kinase 14	Homo sapiens	335-343	
26474590-11	2016	These data suggest that naringin may have therapeutic potential for controlling invasiveness of malignant gliomas by inhibiting of p38 signal transduction pathways.	naringin	24-32	mitogen-activated protein kinase 14	Homo sapiens	131-134	
26474590-0	2016	Naringin inhibits the invasion and migration of human glioblastoma cell via downregulation of MMP-2 and MMP-9 expression and inactivation of p38 signaling pathway.	naringin	0-8	mitogen-activated protein kinase 14	Homo sapiens	141-144	
19885011-4	2009	Naringin also blocked rotenone-induced phosphorylation of Jun NH2-terminal protein kinase (JNK) and P38, and prevented changes in B-cell CLL/lymphoma 2 (BCL2) and BCL2-associated X protein (BAX) expression levels.	naringin	0-8	mitogen-activated protein kinase 14	Homo sapiens	100-103	
18296682-5	2008	Moreover, treatment with naringin induced phosphorylation of extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinase and c-Jun N-terminal kinase.	naringin	25-33	mitogen-activated protein kinase 14	Homo sapiens	106-109